Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Enanta Pharmaceuticals, Inc clinical trials
The registry lists 45 studies whose lead sponsor is Enanta Pharmaceuticals, Inc. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 19, 2026.
Keep track of what changes. Save the Enanta Pharmaceuticals, Inc studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Enanta Pharmaceuticals, Inc.
- Enanta Pharmaceuticals, Inc45 studiesSame company
Something wrong?
Focus areas
Conditions Enanta Pharmaceuticals, Inc leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 45 of 45.
- A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial VirusRecruitingNCT07482657Phase 2
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy AdultsRecruitingNCT07540910Phase 1
- A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.CompletedNCT05568706Phase 2
- A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge ModelCompletedNCT06170242Phase 2
- A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy AdultsCompletedNCT06601192Phase 1
- A Study to Evaluate EDP 938 Regimens in Children With RSVCompletedNCT04816721Phase 2
- A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.CompletedNCT06847464Phase 1
- A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy ParticipantsCompletedNCT06917508Phase 1
- Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory TractTerminatedNCT04633187Phase 2
- A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19CompletedNCT05616728Phase 2
- A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult SubjectsCompletedNCT04196101Phase 2
- A Study of EDP-323 in Healthy SubjectsCompletedNCT05587478Phase 1
- A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASHTerminatedNCT04378010Phase 2
- Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.CompletedNCT05594602Phase 1
- Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy SubjectsCompletedNCT05594615Phase 1
- A Study of EDP-235 in Healthy SubjectsCompletedNCT05246878Phase 1
- A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge ModelCompletedNCT03691623Phase 2
- Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male SubjectsCompletedNCT04927793Phase 1
- A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.TerminatedNCT04971512Phase 1
- A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)CompletedNCT04008004Phase 1
- A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on TreatmentCompletedNCT04470388Phase 1
- A Study of EDP-297 in Healthy SubjectsCompletedNCT04559126Phase 1
- Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy SubjectsCompletedNCT04498741Phase 1
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic SteatohepatitisCompletedNCT03421431Phase 2
- Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy SubjectsCompletedNCT04783753Phase 1
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary CholangitisCompletedNCT03394924Phase 2
- Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy SubjectsCompletedNCT04871724Phase 1
- A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female SubjectsCompletedNCT03783897Phase 1
- Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy SubjectsCompletedNCT03755778Phase 1
- Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult SubjectsCompletedNCT03750383Phase 1
- Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy VolunteersCompletedNCT03610945Phase 1
- Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male SubjectsCompletedNCT03748628Phase 1
- A Study of EDP-938 in Healthy SubjectsCompletedNCT03384823Phase 1
- A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy VolunteersCompletedNCT03207425Phase 1
- Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy VolunteersCompletedNCT03213145Phase 1
- A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLDCompletedNCT02918929Phase 1
- Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.CompletedNCT03187496Phase 1
- EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C PatientsCompletedNCT02652377Phase 1
- Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C SubjectsCompletedNCT01856426Phase 1
- Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788TerminatedNCT02255968Phase 1
- Two-way Interaction Between Alisporivir and EDP239CompletedNCT02173574Phase 1
- Evaluation of the Safety and Pharmacokinetics of a Single Oral Dose of EDP-788CompletedNCT01999725Phase 1
- Multiple Ascending-Dose Study of EDP 322 in Healthy Adult VolunteersCompletedNCT00990145Phase 1
- Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy VolunteersCompletedNCT00989872Phase 1
- Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired PneumoniaStatus unknownNCT00270517Phase 2